使用Player FM应用程序离线!
Key Decisions in HIV Care: ART Considerations With Coinfections
Manage episode 317190610 series 2884624
In this episode from the series “Key Decisions in HIV Care,” Daria Podlekareva, MD, PhD, and Mark S. Sulkowski, MD, discuss important considerations for ART use in patients with coinfections, including:
- DHHS testing and treatment recommendations for HBV in patients with HIV
- Data suggesting that tenofovir alone may not suppress HBV in all PWH
- Data from NA-ACCORD showing that incomplete HBV DNA suppression is associated with HCC in patients with HIV/HBV
- Data for the use of entecavir as an add-on therapy if an HIV ART regimen is not HBV active
- Data showing that lamivudine alone is associated with resistance in patients with HIV/HBV
- Discussion of HBV management in the setting of 2-drug regimens for HIV if the patient is coinfected
- Recommendations from the DHHS, EACS, and WHO to start ART as soon as possible in patients with TB/HIV coinfection
- Data from the SAPiT, ACTG A5221 STRIDE, and CAMELIA studies to show the benefits of early ART in patients with TB/HIV
- Recommendations from the EACS guidelines on what ART regimens are recommended with TB/HIV
- Drug-drug interaction considerations between ART and TB treatment
- Discussion of the prevention and management of TB-associated IRIS
Presenters:
Daria Podlekareva, MD, PhD
Centre of Excellence for Health, Immunity and Infection (CHIP)
Rigshospital, University of Copenhagen
Copenhagen, Denmark
Mark S. Sulkowski, MD
Professor of Medicine
Medical Director, Viral Hepatitis Center
Chief, Infectious Disease
Johns Hopkins Bayview Medical Center
Johns Hopkins University School of Medicine
Baltimore, Maryland
Content based on an online CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; and ViiV Healthcare.
Follow along with slides:
https://bit.ly/3zHySMO
See the entire program at:
https://bit.ly/2TXTYWx
378集单集
Manage episode 317190610 series 2884624
In this episode from the series “Key Decisions in HIV Care,” Daria Podlekareva, MD, PhD, and Mark S. Sulkowski, MD, discuss important considerations for ART use in patients with coinfections, including:
- DHHS testing and treatment recommendations for HBV in patients with HIV
- Data suggesting that tenofovir alone may not suppress HBV in all PWH
- Data from NA-ACCORD showing that incomplete HBV DNA suppression is associated with HCC in patients with HIV/HBV
- Data for the use of entecavir as an add-on therapy if an HIV ART regimen is not HBV active
- Data showing that lamivudine alone is associated with resistance in patients with HIV/HBV
- Discussion of HBV management in the setting of 2-drug regimens for HIV if the patient is coinfected
- Recommendations from the DHHS, EACS, and WHO to start ART as soon as possible in patients with TB/HIV coinfection
- Data from the SAPiT, ACTG A5221 STRIDE, and CAMELIA studies to show the benefits of early ART in patients with TB/HIV
- Recommendations from the EACS guidelines on what ART regimens are recommended with TB/HIV
- Drug-drug interaction considerations between ART and TB treatment
- Discussion of the prevention and management of TB-associated IRIS
Presenters:
Daria Podlekareva, MD, PhD
Centre of Excellence for Health, Immunity and Infection (CHIP)
Rigshospital, University of Copenhagen
Copenhagen, Denmark
Mark S. Sulkowski, MD
Professor of Medicine
Medical Director, Viral Hepatitis Center
Chief, Infectious Disease
Johns Hopkins Bayview Medical Center
Johns Hopkins University School of Medicine
Baltimore, Maryland
Content based on an online CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; and ViiV Healthcare.
Follow along with slides:
https://bit.ly/3zHySMO
See the entire program at:
https://bit.ly/2TXTYWx
378集单集
Все серии
×欢迎使用Player FM
Player FM正在网上搜索高质量的播客,以便您现在享受。它是最好的播客应用程序,适用于安卓、iPhone和网络。注册以跨设备同步订阅。